Rahul Kakkar, Tome Biosciences CEO
January 2, 2024 07:00 AM EST
Deals
Cell/Gene Tx

Ex­clu­sive: Weeks af­ter $213M launch, Tome ac­quires a Berke­ley gene edit­ing start­up for DNA lig­ase tech­nol­o­gy

Ryan Cross

Senior Science Correspondent

Less than a month af­ter launch­ing with $213 mil­lion in fund­ing, gene edit­ing com­pa­ny Tome Bio­sciences has ac­quired a tiny Cal­i­forn­ian start­up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times